Shots:

• ImaginAb signs a multi-year agreement with AstraZeneca- Pfizer & Takeda for the development of ImaginAb's CD8 ImmunoPET technology. The global companies will get early access to clinical and imaging data & will contribute in post-trial data analysis in exchange for helping ImaginAb’s current clinical studies
• The focus of the agreement is to streamline the clinical development of next-generation cancer immunotherapies and to further develop CD8 ImmunoPET as a pharmacodynamic marker for use in drug development
• ImaginAb's technology utilizes its Minibody' platform to target & visualize CD8+ T cells & is used for non-invasive PET imaging of CD8 T cells in patients- providing highly-specific- quantitative assessment of the immunological status of each cancer lesion within a patient thus enabling the quick treatment meeting the need of patients

Click here to­ read full press release/ article | Ref: ImaginAb | Image: LinkedIn